Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;183(3):589-591.
doi: 10.1111/bjd.19266. Epub 2020 Jun 28.

Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy

A Carugno  1 , P Sena  1 , F Raponi  1 , E Robustelli Test  2 , P Vezzoli  1
Affiliations

Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy

A Carugno et al. Br J Dermatol. 2020 Sep.
No abstract available

PubMed Disclaimer

References

    1. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID‐19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; in press [10.1001/jama.2020.4031] - DOI - PubMed
    1. Buoro S, Di Marco F, Rizzi M et al. Papa Giovanni XXIII Bergamo Hospital at the time of the COVID‐19 outbreak: letter from the warfront. Int J Lab Hematol 2020; 42(Suppl. 1):8–10. - PubMed
    1. Ren Z, Narla S, Hsu DY, Silverberg JI. Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol 2018; 32:1768–76. - PubMed
    1. Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse (SIDeMaST). Vademecum per i pazienti affetti da malattie bollose e malattie auto immune [Guide for patients with bullous diseases and autoimmune diseases]. Available at: https://www.sidemast.org/blog/infezione-da-coronavirus-vademecum-per-i-p... (last accessed 27 May 2020).
    1. Rademaker M, Baker C, Foley P et al. Advice regarding COVID‐19 and use of immunomodulators, in patients with severe dermatological diseases. Australas J Dermatol 2020; 61:158–9. - PMC - PubMed

MeSH terms

Substances